Celadon Pharmaceuticals
Celadon Pharmaceuticals this week passed a ‘significant milestone’ as it completed its first ever supply delivery to clients, just days after the successful completion of a £2m fundraise through a placement of new ordinary shares.
The AIM-listed medical cannabis operator issued 1.7m new shares at a price of 115p per share, which are expected to be admitted to AIM on December 18.
This comes as the company continues to seek further funding through the issuance of convertible loan notes, aiming to raise funds ‘in addition to the net proceeds received by the company’ via its share issue.
According to the company: “Subsequent to the expressions of interest received from potential investors at the time of CLN Financing announcement (October 13), additional potential investors have expressed an interest in subscribing for the Convertible Loan Notes and the directors are…
